New safety-focused analysis is putting pressure on the autoimmune risk thesis for certain CAR T designs, with attention on IEC-HS risk as developers test why some events may occur. The coverage highlights that developers are pointing to multiple determinants—including rapid manufacturing, construct design, and patient-specific biology—as potential contributors. The discussion centers on “fatal toxicities” and the hypothesis that autoimmune mechanisms may be involved, an area of intense scrutiny for both regulators and clinicians as CAR T indications expand. CAR T-related IEC-HS refers to immune-effector cell–associated hemophagocytic syndrome, a severe hyperinflammatory complication. For biotech teams, the key implication is operational and biologic: if safety outcomes hinge on more than one variable, risk mitigation will likely require tighter end-to-end controls, including manufacturing parameters and patient monitoring. The next critical step for the field is whether prospective studies can separate the relative contribution of construct features versus manufacturing timing and patient immune states, which would guide safer next-generation designs.